🔗 Share this article

While America continues making unprecedented revisions to its immunization recommendations, a particular individual appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by casting doubt on COVID-19 shots during the global health crisis and has zeroed in on alleged deaths following Covid vaccination in her brief tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Schedule

Agency leaders had intended to reveal radical changes to the pediatric vaccination calendar in December, bringing the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with many the international standard with no evidence for public health gain. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Høeg is listed to address the audience at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to run the division this year.

A Shift at the FDA

This interim role could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad solidify control at the agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for halting specific childhood shot schedules in the US in order to be more in line with Denmark, a country with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Expertise

Høeg has no apparent experience in pharmaceutical research, approval processes or leadership, which has been standard for past leaders of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a large organization. She lacks background in industry regulation.”

Past directors of the center would “grasp regulatory frameworks and the science of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

CDER has an enormous workload at the FDA, Woodcock stated.

“The public just pays attention on the new drug program, but the generic drug division authorizes numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be managed,” she noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major leadership component to the position, which manages more than 5,000 staff members. “It is a huge leadership role, if you execute it properly,” she concluded.

Official Statement and Contentious Initiatives

When asked about concerns about Høeg’s qualifications and whether this assignment indicates greater collaboration among agency officials on immunizations, a representative stated that the “questions are based on incorrect assumptions”.

“Her resume matches the duties of her job,” the representative explained, noting the time Høeg spent advising the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious expedited drug-approval program that apparently worried her predecessors. “How are these therapies being chosen for this fast-track system? Who makes the choices?” Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the FDA seems to be moving towards more relaxed regulations of all drugs, except for immunizations.”

Established History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, past, critics have noted. She published a analysis using unconfirmed public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the new administration featured changing rules for recently developed shots and discontinuing “non-essential” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has reportedly suggested barring adolescent males from receiving Covid vaccines.

“She’s an all-around true believer who starts off with her preconceived notions and works backwards to accommodate the evidence in a very deceptive, dishonest manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|